2-[[3-[(E)-hex-1-enyl]imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol | 1034621-99-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[[3-[(E)-hex-1-enyl]imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol
• 英文别名: (E)-2-(3-(hex-1-enyl)imidazo[1,2-b]pyridazin-6-ylamino)butan-1-ol
• CAS: 1034621-99-2
• 化学式: C₁₆H₂₄N₄O
• 分子量: 288.393
• InChiKey: AGOJOUHRGITLIB-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(3-bromoimidazo[1,2-b]pyridazin-6-ylamino)butan-1-ol 、 反式-1-己烯-1-基硼酸 生成 2-[[3-[(E)-hex-1-enyl]imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol
  参考文献：
  名称：

  6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions

  摘要：

  本文披露了使用6-氨基咪唑[1,2-b]吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的病症的方法，包括控制眼内压和治疗青光眼。本文还披露了眼科制药组合物，对于治疗眼部疾病如青光眼，以及控制眼内压具有额外的用途，该组合物包括6-氨基咪唑[1,2-b]吡嗪类似物的有效量。

  公开号：

  US07820670B2

文献信息

• 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS
  申请人：CHEN Hwang-Hsing

  公开号：US20080153813A1

  公开（公告）日：2008-06-26

  Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

  本文披露了使用6-氨基咪唑并[1,2-b]吡啶嗪类似物治疗rho激酶介导的疾病或rho激酶介导的症状的方法，包括控制眼压和治疗青光眼。本文还披露了用于治疗眼部疾病如青光眼，并且对控制眼压有益的眼科药物组合物，该组合物包括有效量的6-氨基咪唑并[1,2-b]吡啶嗪类似物。
• Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2818471A1

  公开（公告）日：2014-12-31

  The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.

  本发明涉及假设能够调节蛋白质ScyI1和Grk5活性的化合物，从而调节胰岛素的表达和/或释放，以及包含此类化合物的药物组合物及其用途，特别是用于治疗糖尿病、肥胖和脂肪生成受损等代谢性疾病。
• KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20150079108A1

  公开（公告）日：2015-03-19

  The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
• US7820670B2
  申请人：——

  公开号：US7820670B2

  公开（公告）日：2010-10-26
• US9458463B2
  申请人：——

  公开号：US9458463B2

  公开（公告）日：2016-10-04